Child & adolescent social work journal : C & A · 2023
Resilience in Adolescent Girls in Child Welfare: Reliability and Validity of the RS-14.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Friesen Claudia, Roscher Mareike, Hormann Inis, Fichtner Iduna, Alt Andreas, Hilger Ralf A, Debatin Klaus-Michael, Miltner Erich
Аннотация
PURPOSE: Up to one-third of patients treated with primary radiotherapy (RT) for prostate cancer (PCa) experience biochemical failure (BCF). In selected cases, re-irradiation represents a salvage option. PSMA PET/CT is a valuable tool for detecting intraprostatic recurrence and guiding re-treatment planning. Although visual scoring systems such as the PRIMARY score (PS) have been proposed, none are currently validated for this setting. This pilot study investigates the role of a visual classification system in optimizing salvage re-irradiation strategies.
METHODS: We retrospectively analysed patients with histologically confirmed PCa who underwent re-irradiation for intraprostatic recurrence, following PSMA PET/CT between 2021 and 2024. Only patients without extra-prostatic disease were included. Clinical, imaging, and treatment data were collected. Re-irradiation was delivered using image-guided volumetric modulated arc therapy. Outcomes included BCF and toxicity (CTCAE v5).
RESULTS: Thirteen patients (median age: 76 years) were included. The International Society of Urological Pathology (ISUP) grade group at diagnosis was 1-2 in ten patients and ≥ 4 in three. Median PSA at diagnosis and at re-irradiation was 9.43 and 2.22 ng/mL, respectively. PSMA PET/CT showed uptake in all cases (focal: 8, diffuse: 4, mixed: 1); PS was ≥ 4 in eight patients. Re-irradiation was delivered after a mean interval of 8.1 years, with a median dose of 30 Gy in 5 fractions. PET/CT guided target delineation in 11 cases. After 16 months of median follow-up, four patients had BCF, and two experienced mild toxicity (Grade 1).
CONCLUSION: These preliminary findings highlight the limitations of visual interpretation alone; further optimization by Nuclear Medicine and Radiation Oncology specialists is needed to enhance BCF and limit local toxicities.
METHODS: We retrospectively analysed patients with histologically confirmed PCa who underwent re-irradiation for intraprostatic recurrence, following PSMA PET/CT between 2021 and 2024. Only patients without extra-prostatic disease were included. Clinical, imaging, and treatment data were collected. Re-irradiation was delivered using image-guided volumetric modulated arc therapy. Outcomes included BCF and toxicity (CTCAE v5).
RESULTS: Thirteen patients (median age: 76 years) were included. The International Society of Urological Pathology (ISUP) grade group at diagnosis was 1-2 in ten patients and ≥ 4 in three. Median PSA at diagnosis and at re-irradiation was 9.43 and 2.22 ng/mL, respectively. PSMA PET/CT showed uptake in all cases (focal: 8, diffuse: 4, mixed: 1); PS was ≥ 4 in eight patients. Re-irradiation was delivered after a mean interval of 8.1 years, with a median dose of 30 Gy in 5 fractions. PET/CT guided target delineation in 11 cases. After 16 months of median follow-up, four patients had BCF, and two experienced mild toxicity (Grade 1).
CONCLUSION: These preliminary findings highlight the limitations of visual interpretation alone; further optimization by Nuclear Medicine and Radiation Oncology specialists is needed to enhance BCF and limit local toxicities.